Imunon (NASDAQ: IMNN) ups ATM program by $7M to $17M capacity

Rhea-AI Filing Summary

Imunon, Inc. amends its ATM prospectus supplement to increase the aggregate amount available for sale under its At the Market Offering Agreement with H.C. Wainwright & Co. to $17,000,000, adding $7,000,000 to the prior $10,000,000 authorization.

The sales program permits the company to offer and sell Common Stock from time to time pursuant to the Sales Agreement dated May 25, 2022, as amended. Through the date of this supplement the company has sold $4,797,848 under the program.

Insights

Capital Markets Strategist

Increases ATM capacity by $7.0M to a $17.0M program.

The company expands its at-the-market (ATM) equity availability under the Sales Agreement with H.C. Wainwright & Co., raising the program ceiling to $17,000,000. The supplement states $4,797,848 has been sold to date under the agreement.

This amendment is an issuance-enabling action; actual share issuance depends on future sales decisions by the company and market conditions. Cash-flow treatment is proceeds-to-issuer under the ATM mechanics described in the supplement.

Securities Counsel

Legal filing updates the prospectus to reflect expanded ATM capacity.

The prospectus supplement amends the Registration Statement and the ATM Prospectus Supplement, and references the Sales Agreement as the operative distribution mechanism. The supplement preserves previously disclosed risk-factor cross-references and counsel opinion attribution.

Qualifiers such as the Sales Agreement and prior sales are explicitly stated; future sales remain subject to the Sales Agreement terms and market execution choices.

Filed Pursuant to Rule 424(b)(5)

Registration No. 333-279425

PROSPECTUS SUPPLEMENT NO. 3

(to Prospectus dated May 22, 2024,

Prospectus Supplement dated September 3, 2024, and

Prospectus Supplement dated July 22, 2025)

IMUNON, INC.

Up to $17,000,000 of Common Stock

This prospectus supplement amends and supplements the information in the prospectus supplement, dated September 3, 2024, as amended and supplemented by the prospectus supplement dated July 22, 2025 (as amended and supplemented, the “ATM Prospectus Supplement”), to the accompanying base prospectus, dated May 22, 2024 (the “Base Prospectus” and, collectively with the ATM Prospectus Supplement, the “Prospectus”) filed as part of our registration statement on Form S-3 (File No. 333-279425) (the “Registration Statement”), relating to the offer, issuance and sale of shares of our common stock, par value $0.01 per share (“Common Stock”), from time to time pursuant to the terms of an At the Market Offering Agreement, dated as of May 25, 2022, as amended by Amendment No. 1 to At the Market Offering Agreement, dated as of May 15, 2024 (as amended, the “Sales Agreement”), by and between us and H.C. Wainwright & Co., LLC, as sales agent or principal (“Wainwright” or the “sales agent”). Through the date hereof, we have sold an aggregate of $4,797,848 of shares of our Common Stock through the sales agent under the Sales Agreement. This prospectus supplement should be read in conjunction with the Prospectus, and is qualified by reference thereto, except to the extent that the information herein amends or supersedes the information contained in the Prospectus. This prospectus supplement is not complete without, and may only be delivered or utilized in connection with, the Prospectus, and any future amendments or supplements thereto.

We are filing this prospectus supplement to amend and supplement the Prospectus to increase the aggregate amount we intend to sell pursuant to the Sales Agreement. As of the date of this prospectus supplement, we are offering up to an aggregate of $17,000,000 of our Common Stock for sale under the Sales Agreement, consisting of $10,000,000 that was previously authorized pursuant to the ATM Prospectus Supplement and an additional $7,000,000 pursuant to this prospectus supplement.

Our Common Stock is listed on The Nasdaq Stock Market LLC under the symbol “IMNN.” On March 19, 2026, the last reported sale price for our Common Stock on Nasdaq was $2.95 per share.

The validity of the shares being offered hereby will be passed upon by Thompson Hine LLP.

Investing in our securities involves a high degree of risk. Before making an investment decision, please read “Risk Factors” beginning on page S-3 of the ATM Prospectus Supplement dated September 3, 2024 and the other documents and information contained or incorporated by reference in this prospectus supplement and the ATM Prospectus Supplement.

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus supplement is truthful or complete. Any representation to the contrary is a criminal offense.

H.C. Wainwright & Co.

The date of this prospectus supplement is March 23, 2026 

FAQ

What did Imunon (IMNN) change in this prospectus supplement?

The company increased its ATM offering capacity to $17,000,000, adding $7,000,000 to the prior $10,000,000 authorization. This amendment updates the prospectus supplement governing sales under the Sales Agreement with H.C. Wainwright.

How much has Imunon already sold under the Sales Agreement?

Through the date of the supplement Imunon sold $4,797,848 of Common Stock under the Sales Agreement. That figure is reported in the prospectus supplement as the cumulative amount sold to date under the ATM program.

Who is acting as sales agent for Imunon's ATM program?

H.C. Wainwright & Co., LLC is the sales agent or principal under the At the Market Offering Agreement, as amended. The Sales Agreement dated May 25, 2022 governs offering mechanics and was amended May 15, 2024.

Will Imunon receive proceeds from share sales under this ATM program?

Yes. The prospectus supplement describes sales of Common Stock 'for sale under the Sales Agreement,' indicating proceeds from shares sold through the ATM would be received by the issuer per the Sales Agreement mechanics.